NASDAQ:DRTS

Alpha Tau Medical Stock News

Healthcare > Biotechnology

Buy DRTS

*Your capital is at risk

$11.79

-0.100 (-0.84%)

At Close: Jul 31, 2026

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

08:30am, Tuesday, 11'th Nov 2025

JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

08:30am, Tuesday, 21'st Oct 2025

- Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

11:55am, Thursday, 16'th Oct 2025

Alpha DaRT, a unique localized alpha radiation therapy, has shown potential best-in-class efficacy and safety across multiple solid tumors. Currently enrolling patients in cSCC, HNSCC, pancreatic, and

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by